The FDA is revising the labeling of all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD) – including certain formulations of amphetamine and methylphenidate – to warn about the risk of weight loss and other adverse reactions (side effects) in patients yo
Similar Posts
Safety Labeling Changes—Implementation of Section 505(o)(4) of the FD&C Act
This draft guidance provides information on the implementation of the statutory provision that authorizes FDA to require application holders for certain drug and biological products to make labeling changes based on new safety information that becomes available after approval of the drug.Aurobindo Pharma Ltd. Unit-XII – 09/5/2025
Aurobindo Pharma Ltd. Unit-XII – 09/5/2025. Country: India. Record Type: 483Giant Eagle Recalls Smoked Mozzarella Pasta Salad Due to Potential Listeria Monocytogenes Contamination Associated with Nationwide Recall from Nate’s Fine Foods
PITTSBURGH – Giant Eagle, Inc., has issued a voluntary recall of “Smoked Mozzarella Pasta Salad” sold in the prepared foods departments of its Giant Eagle and Market District locations across western Pennsylvania, Ohio, Maryland and Indiana due to potential listeria monocytogenes contamination. ThisFDA Approves Labeling Changes that Include a Boxed Warning for Immune Effector Cell-associated Enterocolitis Following Treatment with Ciltacabtagene Autoleucel (CARVYKTI, Janssen Biotech, Inc.)
The FDA has received reports of immune effector cell-associated enterocolitis (IEC-EC) in patients who received treatment with CARVYKTI.Other | Cancer Accelerated Approvals
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have been granted for supportive care products and changes to dosing or formulation.Executive Order 14017 on America’s Supply Chains
Updates on recommendations to help shore up the U.S. pharmaceutical supply chain, as directed by Executive Order 14017 on America’s Supply Chains